Stock Events

Stock Events

EyeGene 

₩1,713
2
-₩31-1.78% 06:30 Today

Statistics

Day High
1,769
Day Low
1,685
52W High
2,805
52W Low
1,182
Volume
48,541
Avg. Volume
141,301
Mkt Cap
46.3B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Dec 31Expected
Q1 2017
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
-194
-145
-97
-49
Expected EPS
N/A
Actual EPS
-49

Financials

-440.34%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
3.57BRevenue
-15.71BNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Seegene
096530.KQ
Mkt Cap1.3T
Celltrion Health Care
091990.KQ
Mkt Cap11.33T
Cellivery Therapeutics, Inc. specializes in drug delivery technology, which competes with EyeGene's innovative drug delivery systems in the biopharmaceutical sector.
Medy-Tox
086900.KQ
Mkt Cap471.87B
Medy-Tox Inc. develops botulinum toxin products and biopharmaceuticals, competing with EyeGene in the biopharmaceutical sector focusing on innovative therapeutic solutions.
Ildong Pharm
249420.KQ
Mkt Cap0
Tego Science Inc. specializes in cell therapy products for regenerative medicine, which competes with EyeGene's focus on innovative therapeutic treatments in biopharmaceuticals.
Seoul ViosysLtd
092190.KQ
Mkt Cap331.07B
Genexine, Inc. is engaged in the research and development of biopharmaceuticals, particularly in the therapeutic protein area, competing with EyeGene in the biopharmaceutical innovation sector.

About

EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury. It also develops EG-HZ, which has completed phase 1 clinical trial for the treatment of herpes zoster; EG-HPV which completed Phase 1 clinical trial to treat cervical cancer; EG-COVID that is in phase I clinical trial for the treatment of covid; and EG-TB for the tuberculosis vaccine and is in preclinical trial. In addition, the company offers vitalDB for beautiful vitality. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
Show More
CEO
Mr. Won-Il Yoo
Employees
47
Country
South Korea
ISIN
KR7185490000

Listings

KQ
KR
185490.KQ

0 Comments

Share your thoughts

FAQs

What is EyeGene stock price today?▼
The current price of 185490.KQ is ₩1,713 KRW — it has decreased by -1.78% in the past 24 hours. Watch EyeGene stock price performance more closely on the chart.
What is EyeGene stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on KOSDAQ exchange EyeGene stocks are traded under the ticker 185490.KQ.
Is EyeGene stock price growing?▼
185490.KQ stock has fallen by -2.06% compared to the previous week, the month change is a -10.69% fall, over the last year EyeGene has showed a -4.62% decrease.
What is EyeGene market cap?▼
Today EyeGene has the market capitalization of 46.3B
What were EyeGene earnings last quarter?▼
185490.KQ earnings for the last quarter are -49 KRW per share, whereas the estimation was N/A KRW resulting in a N/A surprise. The estimated earnings for the next quarter are N/A KRW per share.
What is EyeGene revenue for the last year?▼
EyeGene revenue for the last year amounts to 3.57B KRW.
What is EyeGene net income for the last year?▼
185490.KQ net income for the last year is -15.71B KRW.
How many employees does EyeGene have?▼
As of November 3, 2026, the company has 47 employees.
In which sector is EyeGene located?▼
EyeGene operates in the Energy sector.
When did EyeGene complete a stock split?▼
The last stock split for EyeGene was on June 28, 2021 with a ratio of 1.2:1.
Where is EyeGene headquartered?▼
EyeGene is headquartered in Seoul, South Korea.